Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946110> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4361946110 abstract "<div>Abstract<p><b>Purpose:</b> Targeted treatment of solid or liquid tumors with antibody–drug conjugates (ADCs) can lead to promising clinical benefit. The aim of the study is to investigate combination regimens of auristatin-based ADCs in preclinical models of cancer.</p><p><b>Experimental Design:</b> An auristatin-based anti-5T4 antibody conjugate (5T4-ADC) and auristatin payloads were combined with the dual PI3K/mTOR catalytic site inhibitor PF-05212384 (PF-384) or taxanes in a panel of tumor cell lines. Drug interactions <i>in vitro</i> were evaluated using cell viability assays, apoptosis induction, immunofluorescence, mitotic index, and immunoblotting. Breast cancer cells treated with auristatin analogue or 5T4-ADC were profiled by total- and phospho-proteomics. Antitumor efficacy of selected combinations was evaluated in 5T4-positive human breast or lung tumor xenografts <i>in vivo</i>.</p><p><b>Results:</b><i>In vitro</i>, auristatin-based agents displayed strong synergistic or additive activity when combined with PF-384 or taxanes, respectively. Further, treatment of 5T4-ADC plus PF-384 resulted in stronger induction of apoptosis and cell line–specific attenuation of pAKT and pGSK. Interestingly, proteomic analysis revealed unique effects of auristatins on multiple components of mRNA translation. Addition of PF-384 further amplified effects of 5T4-ADC on translational components, providing a potential mechanism of synergy between these drugs. In human tumor xenografts, dual targeting with 5T4-ADC/PF-384 or 5T4-ADC/paclitaxel produced substantially greater antitumor effects with longer average survival as compared with monotherapy treatments.</p><p><b>Conclusions:</b> Our results provide a biologic rationale for combining 5T4-ADC with either PI3K/mTOR pathway inhibitors or taxanes and suggest that mechanisms underlying the synergy may be attributed to cellular effects of the auristatin payload. <i>Clin Cancer Res; 22(2); 383–94. ©2015 AACR</i>.</p></div>" @default.
- W4361946110 created "2023-04-05" @default.
- W4361946110 creator A5002661071 @default.
- W4361946110 creator A5006428715 @default.
- W4361946110 creator A5014632539 @default.
- W4361946110 creator A5026185361 @default.
- W4361946110 creator A5026916229 @default.
- W4361946110 creator A5052939374 @default.
- W4361946110 creator A5084750823 @default.
- W4361946110 creator A5086209067 @default.
- W4361946110 creator A5088512702 @default.
- W4361946110 date "2023-03-31" @default.
- W4361946110 modified "2023-10-16" @default.
- W4361946110 title "Data from Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes" @default.
- W4361946110 doi "https://doi.org/10.1158/1078-0432.c.6524079" @default.
- W4361946110 hasPublicationYear "2023" @default.
- W4361946110 type Work @default.
- W4361946110 citedByCount "0" @default.
- W4361946110 crossrefType "posted-content" @default.
- W4361946110 hasAuthorship W4361946110A5002661071 @default.
- W4361946110 hasAuthorship W4361946110A5006428715 @default.
- W4361946110 hasAuthorship W4361946110A5014632539 @default.
- W4361946110 hasAuthorship W4361946110A5026185361 @default.
- W4361946110 hasAuthorship W4361946110A5026916229 @default.
- W4361946110 hasAuthorship W4361946110A5052939374 @default.
- W4361946110 hasAuthorship W4361946110A5084750823 @default.
- W4361946110 hasAuthorship W4361946110A5086209067 @default.
- W4361946110 hasAuthorship W4361946110A5088512702 @default.
- W4361946110 hasConcept C150903083 @default.
- W4361946110 hasConcept C159654299 @default.
- W4361946110 hasConcept C185592680 @default.
- W4361946110 hasConcept C190283241 @default.
- W4361946110 hasConcept C202751555 @default.
- W4361946110 hasConcept C203014093 @default.
- W4361946110 hasConcept C207001950 @default.
- W4361946110 hasConcept C2777325958 @default.
- W4361946110 hasConcept C502942594 @default.
- W4361946110 hasConcept C542903549 @default.
- W4361946110 hasConcept C55493867 @default.
- W4361946110 hasConcept C71924100 @default.
- W4361946110 hasConcept C86554907 @default.
- W4361946110 hasConcept C86803240 @default.
- W4361946110 hasConcept C98274493 @default.
- W4361946110 hasConceptScore W4361946110C150903083 @default.
- W4361946110 hasConceptScore W4361946110C159654299 @default.
- W4361946110 hasConceptScore W4361946110C185592680 @default.
- W4361946110 hasConceptScore W4361946110C190283241 @default.
- W4361946110 hasConceptScore W4361946110C202751555 @default.
- W4361946110 hasConceptScore W4361946110C203014093 @default.
- W4361946110 hasConceptScore W4361946110C207001950 @default.
- W4361946110 hasConceptScore W4361946110C2777325958 @default.
- W4361946110 hasConceptScore W4361946110C502942594 @default.
- W4361946110 hasConceptScore W4361946110C542903549 @default.
- W4361946110 hasConceptScore W4361946110C55493867 @default.
- W4361946110 hasConceptScore W4361946110C71924100 @default.
- W4361946110 hasConceptScore W4361946110C86554907 @default.
- W4361946110 hasConceptScore W4361946110C86803240 @default.
- W4361946110 hasConceptScore W4361946110C98274493 @default.
- W4361946110 hasLocation W43619461101 @default.
- W4361946110 hasOpenAccess W4361946110 @default.
- W4361946110 hasPrimaryLocation W43619461101 @default.
- W4361946110 hasRelatedWork W1983855168 @default.
- W4361946110 hasRelatedWork W2050306700 @default.
- W4361946110 hasRelatedWork W2080089609 @default.
- W4361946110 hasRelatedWork W2328739198 @default.
- W4361946110 hasRelatedWork W2382426014 @default.
- W4361946110 hasRelatedWork W2385215236 @default.
- W4361946110 hasRelatedWork W2433311123 @default.
- W4361946110 hasRelatedWork W2953758866 @default.
- W4361946110 hasRelatedWork W3039655065 @default.
- W4361946110 hasRelatedWork W3165143150 @default.
- W4361946110 isParatext "false" @default.
- W4361946110 isRetracted "false" @default.
- W4361946110 workType "article" @default.